Ovarian cancer recurrence: Role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose

European Journal of Nuclear Medicine

Volumn 29, Issue 6, 2002, Pages 797-803

  Torizuka, Tatsuo ^a   Nobezawa, Shuji ^a   Kanno, Toshihiko ^a   Futatsubashi, Masami ^b   Yoshikawa, Etsuji ^b   Okada, Hiroyuki ^b   Takekuma, Munetaka ^a   Maeda, Makoto ^a   Ouchi, Yasuomi ^a  

^a HAMAMATSU MEDICAL CENTER   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

Author keywords

Conventional imaging; Diagnosis; FDG PET; Recurrent ovarian cancer; Serum CA125 levels

Indexed keywords

CA 125 ANTIGEN; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ABDOMEN; ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PATHOLOGY; PELVIS; POSITRON EMISSION TOMOGRAPHY; IMAGING; SENSITIVITY AND SPECIFICITY; ADENOCARCINOMA; BLOOD; CANCER STAGING; CLINICAL TRIAL; COLLOID CARCINOMA; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GRANULOSA CELL TUMOR; LABORATORY DIAGNOSIS; METHODOLOGY; MIDDLE AGED; OVARY TUMOR; POSTOPERATIVE CARE; REPRODUCIBILITY; SCINTISCANNING; TUMOR RECURRENCE; WHOLE BODY COUNTING;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; CA-125 ANTIGEN; COMPARATIVE STUDY; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; FEMALE; FLUDEOXYGLUCOSE F 18; FOLLOW-UP STUDIES; GRANULOSA CELL TUMOR; HUMAN; MIDDLE AGE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSTOPERATIVE CARE; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; WHOLE-BODY COUNTING; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED;

EID: 0036596897     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-001-0750-9     Document Type: Article

References (23)

1. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer
2. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease?
3. Serum CA125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer
4. Is it possible to differentiate malignant mediastinal nodes from benign nodes by size? Reevaluation by CT, transesophageal echocardiography, and nodal specimen
5. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence
6. Ovarian cancer recurrence: Value of MR imaging
7. Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors
8. Prospective investigation of positron emission tomography in lung nodules
9. 18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma
10. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET
11. 131I-anti-B1 radioimmunotherapy: Evaluation with FDG PET
12. Whole body positron emission tomography in the treatment of Hodgkin disease
13. Staging non-small cell lung cancer with whole-body PET
14. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma
15. 18F]-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma
16. 18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma
17. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: Correlation with second-look laparotomy
18. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer
19. 18F-FDG PET) in diagnosis of ovarian cancer
20. Short dynamic FDG-PET imaging protocol for patients with lung cancer
21. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution
22. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality
23. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The gynecologic oncology group experience